Lucia Masarova, MD, an assistant professor in the Department of Leukemia at the University of Texas MD Anderson, discusses the 2025 EHA late-breaking abstract presented on the novel therapy INCA33989, a first-in-class mutCALR-targeted therapy in essential thrombocythemia.
In the video, Dr. Masarova said that the dose-escalation part of the study progressed well and had “excelling safety with no concerning results.”
The study was presented by John Mascarenhas, MD, during the June 2025 European Hematology Association Congress in Milan. Dr. Mascarenhas presented on the dose-escalation portion of the study in patients with high-risk essential thrombocythemia who are resistant or intolerant to prior cytoreductive therapy.
INCA33989 is currently being investigated in essential thrombocythemia and myelofibrosis in two different, multicenter phase 1 trials as a monotherapy or in combination with ruxolitinib, according to the therapy’s manufacturer, Incyte.
Visit our EHA meeting news page for other content from the meeting.
